223 related articles for article (PubMed ID: 25779947)
1. Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity.
Chua JX; Vankemmelbeke M; McIntosh RS; Clarke PA; Moss R; Parsons T; Spendlove I; Zaitoun AM; Madhusudan S; Durrant LG
Clin Cancer Res; 2015 Jul; 21(13):2963-74. PubMed ID: 25779947
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.
Noble P; Spendlove I; Harding S; Parsons T; Durrant LG
PLoS One; 2013; 8(2):e54892. PubMed ID: 23408949
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Antibody Targeting Sialyl-di-Lewis
Tivadar ST; McIntosh RS; Chua JX; Moss R; Parsons T; Zaitoun AM; Madhusudan S; Durrant LG; Vankemmelbeke M
Mol Cancer Ther; 2020 Mar; 19(3):790-801. PubMed ID: 31871270
[TBL] [Abstract][Full Text] [Related]
4. Molecular and structural basis for Lewis glycan recognition by a cancer-targeting antibody.
Soliman C; Guy AJ; Chua JX; Vankemmelbeke M; McIntosh RS; Eastwood S; Truong VK; Elbourne A; Spendlove I; Durrant LG; Ramsland PA
Biochem J; 2020 Sep; 477(17):3219-3235. PubMed ID: 32789497
[TBL] [Abstract][Full Text] [Related]
5. Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity.
Sawada R; Sun SM; Wu X; Hong F; Ragupathi G; Livingston PO; Scholz WW
Clin Cancer Res; 2011 Mar; 17(5):1024-32. PubMed ID: 21343375
[TBL] [Abstract][Full Text] [Related]
6. Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement.
Vankemmelbeke M; McIntosh RS; Chua JX; Kirk T; Daniels I; Patsalidou M; Moss R; Parsons T; Scott D; Harris G; Ramage JM; Spendlove I; Durrant LG
Cancer Res; 2020 Aug; 80(16):3399-3412. PubMed ID: 32532823
[TBL] [Abstract][Full Text] [Related]
7. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.
Oshima T; Sato S; Kato J; Ito Y; Watanabe T; Tsuji I; Hori A; Kurokawa T; Kokubo T
Mol Cancer; 2013 Jun; 12():60. PubMed ID: 23758976
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
Watanabe M; Ohishi T; Kuzuoka M; Nudelman ED; Stroud MR; Kubota T; Kodairo S; Abe O; Hirohashi S; Shimosato Y
Cancer Res; 1991 Apr; 51(8):2199-204. PubMed ID: 1706961
[TBL] [Abstract][Full Text] [Related]
10. Glycan-Based Near-infrared Fluorescent (NIRF) Imaging of Gastrointestinal Tumors: a Preclinical Proof-of-Concept In Vivo Study.
Houvast RD; Baart VM; Bhairosingh SS; Cordfunke RA; Chua JX; Vankemmelbeke M; Parsons T; Kuppen PJK; Durrant LG; Vahrmeijer AL; Sier CFM
Mol Imaging Biol; 2020 Dec; 22(6):1511-1522. PubMed ID: 32780212
[TBL] [Abstract][Full Text] [Related]
11. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
12. Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
Zhang M; Qian J; Lan Y; Lu Y; Li H; Hong B; Zheng Y; He J; Yang J; Yi Q
Int J Cancer; 2014 Sep; 135(5):1132-41. PubMed ID: 24474467
[TBL] [Abstract][Full Text] [Related]
13. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.
Hatterer E; Chauchet X; Richard F; Barba L; Moine V; Chatel L; Broyer L; Pontini G; Bautzova T; Juan F; Calloud S; Bosson N; Charreton M; Masternak K; Buatois V; Shang L
MAbs; 2020; 12(1):1739408. PubMed ID: 32191151
[TBL] [Abstract][Full Text] [Related]
14. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
Loisel S; André PA; Golay J; Buchegger F; Kadouche J; Cérutti M; Bologna L; Kosinski M; Viertl D; Delaloye AB; Berthou C; Mach JP; Boumsell L
Mol Cancer; 2011 Apr; 10():42. PubMed ID: 21504579
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of a specific IgG monoclonal antibody toward the Lewis x antigen using splenocytes of Schistosoma mansoni-infected mice.
Mandalasi M; Dorabawila N; Smith DF; Heimburg-Molinaro J; Cummings RD; Nyame AK
Glycobiology; 2013 Jul; 23(7):877-92. PubMed ID: 23542315
[TBL] [Abstract][Full Text] [Related]
17. Effects of amino acid substitutions on the biological activity of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
Aoyama M; Tada M; Tatematsu KI; Hashii N; Sezutsu H; Ishii-Watabe A
Biochem Biophys Res Commun; 2018 Sep; 503(4):2633-2638. PubMed ID: 30119885
[TBL] [Abstract][Full Text] [Related]
18. Human monoclonal antibody GNX-8 directed to extended type 1 chain: Specific binding to human colorectal cancer.
Yang MC; Hsu FL; Handa K; Hakomori S; Lee MH; Liu LY; Chang SY; Ting J; Wen JY; Ishida I; Chang TH
Int J Cancer; 2009 Dec; ():. PubMed ID: 20027630
[TBL] [Abstract][Full Text] [Related]
19. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
20. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
